Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CRVO | S-3 | bearish | 6/10 | CervoMed filed an S-3 shelf registration to register 10,081,131 shares of common stock for resale by selling stockholder | Jul 6, 2026 |
| IGC | 8-K | mixed | 5/10 | IGC Pharma issued 4,274,853 shares of common stock to CEO Ram Mukunda and VP/PFO Claudia Grimaldi at $0.27 per share in | Jul 6, 2026 |
| DBVT | PRESS-RELEASE | neutral | 2/10 | DBV Technologies published its semi-annual liquidity contract report with ODDO BHF, detailing share buyback and sales ac | Jul 6, 2026 |
| ABCL | 8-K | neutral | 2/10 | AbCellera appointed Dr. Lynn Seely, an experienced biopharmaceutical executive, as an independent Class III director eff | Jul 6, 2026 |
| BSPK | 8-K | bearish | 6/10 | Bespoke Extracts amended its Senior Secured Promissory Notes on June 30, 2026, extending the maturity from June 30 to Au | Jul 6, 2026 |
| TAK | 3 | neutral | 2/10 | Bruce Broussard filed a Form 3 initial statement of beneficial ownership with the SEC, reporting 795 American Depositary | Jul 6, 2026 |
| HYFT | 6-K | bullish | 5/10 | MindWalk Holdings Corp. (HYFT) has been added to the Russell 3000E Index as part of the FTSE Russell June 2026 semi-annu | Jul 6, 2026 |
| CNTA | 15-12G | bearish | 7/10 | Centessa Pharmaceuticals filed a Form 15-12G on July 6, 2026, to voluntarily deregister its ordinary shares and American | Jul 6, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine 6-K update on its ongoing B share repurchase program, reporting weekly transactions from Ju | Jul 6, 2026 |
| RADX | 6-K | bullish | 5/10 | Radiopharm Theranostics received a A$5.885M R&D tax refund for FY2025 from the Australian government's R&D tax incentive | Jul 6, 2026 |
| CANF | 6-K | bullish | 6/10 | Can-Fite (CANF) announced it has completed enrolment of the first 247 patients in its pivotal Phase 3 study of Piclideno | Jul 6, 2026 |
| IVVD | 8-K | bearish | 6/10 | Invivyd (IVVD) announced receipt of a 12-month advanced notice of EUA termination for its only authorized product, PEMGA | Jul 6, 2026 |
| LIMN | 8-K | bearish | 6/10 | Liminatus Pharma completed its acquisition of InnocsAI LLC via merger on July 2, 2026. The total consideration consists | Jul 6, 2026 |
| ADAG | 6-K | neutral | 3/10 | Adagene disclosed preliminary unaudited cash and cash equivalents of $127.9 million as of June 30, 2026 in a routine 6-K | Jul 6, 2026 |
| IMRN | 6-K | bullish | 6/10 | Immuron engaged Pullan Consulting to assist in securing a strategic partnership for its IMM-529 (C. difficile infection) | Jul 6, 2026 |
| CSCIF | 6-K | bearish | 6/10 | COSCIENS Biopharma completed a 1:150 reverse stock split followed by a 50:1 forward split (net 1:3 reduction) and announ | Jul 6, 2026 |
| OMER | 8-K | neutral | 4/10 | Omeros disclosed the completion of a $16.0M principal repurchase of its 9.50% Convertible Senior Notes due 2029 for ~$31 | Jul 6, 2026 |
| MIRA | 8-K | bullish | 5/10 | MIRA Pharmaceuticals reported positive preclinical pharmacokinetic results for its oral obesity and addiction drug candi | Jul 6, 2026 |
| PBH | PRESS-RELEASE | mixed | 5/10 | Prestige closed its $150M acquisition of LaCorium Health, priced a $400M 6.25% senior notes offering to refinance its 5. | Jul 6, 2026 |
| LYB | PRESS-RELEASE | neutral | 1/10 | LyondellBasell announced it will report its Q2 results on July 31, 2026. | Jul 6, 2026 |
| REGN | 8-K | neutral | 4/10 | Regeneron filed an 8-K pre-announcing an expected ~$127M pre-tax acquired IPR&D charge for Q2 2026, which will reduce GA | Jul 6, 2026 |
| PHVS | PRESS-RELEASE | bullish | 6/10 | Pharvaris announced FDA acceptance of its New Drug Application (NDA) for deucrictibant immediate-release capsules for on | Jul 6, 2026 |
| SCLX | 8-K | mixed | 6/10 | Scilex Holding Company announced a binding term sheet for a proposed $100M strategic investment from Kazakhstan-based iH | Jul 6, 2026 |
| GILD | ANALYST-UPGRADE | bullish | 3/10 | HSBC double-upgraded Gilead Sciences from Hold to Buy on July 6, 2026, raising its price target to $155 from $133, imply | Jul 6, 2026 |
| VXRT | DEFA14A | neutral | 5/10 | Vaxart and the Houle Stockholder Group entered into a Cooperation Agreement on July 1, 2026, ending the proxy contest fo | Jul 6, 2026 |
| PFE | ANALYST-DOWNGRADE | bearish | 4/10 | HSBC double-downgraded Pfizer (PFE) from Buy to Hold on July 6, 2026, slashing the price target to $28 from $32, implyin | Jul 6, 2026 |
| IVA | 6-K | neutral | 2/10 | Inventiva reported the results of its Combined Shareholders General Meeting held June 30, 2026. All 40 resolutions were | Jul 6, 2026 |
| BTAI | 8-K | bearish | 7/10 | BioXcel Therapeutics entered into the Tenth Amendment to its Oaktree credit agreement, deferring a $9.0M payment from Ju | Jul 6, 2026 |
| IMRN | PRESS-RELEASE | bullish | 6/10 | Immuron engaged Pullan Consulting to secure a strategic partner for its IMM-529 program targeting C. difficile infection | Jul 6, 2026 |
| ATAI | PRESS-RELEASE | neutral | 4/10 | AtaiBeckley announced completion of enrollment (156 patients) in the Phase 2b Elumina trial of VLS-01 for treatment-resi | Jul 6, 2026 |